BALF | Placebo (n = 18) | GSK1995057 (n = 18) | % reduction | P-value |
---|---|---|---|---|
PMN (10^{4} cells/ml) | 6.5 (4.5, 9.4) | 4.5 (2.89, 6.89) 3.8 (2.8, 5.3)^{*} | 31 (41)^{†} | 0.17 (0.03)^{†} |
IL-1b (pg/ml) | 6.8 (4.3, 10.4) | 1.4 (1.0, 2.1) | 79 | <0.0001 |
IL-6 (pg/ml) | 386.1 (277.5, 537.4) | 169.4 (111.2, 257.9) | 56 | 0.003 |
IL-8 (pg/ml) | 332.1 (254.6, 433.2) | 117.5 (82.5, 167.54) | 65 | <0.0001 |
MIP1alpha (pg/ml) | 133.7 (87.2, 205.1) | 15.6 (8.3, 29.1) | 88 | <0.0001 |
MCP-1 (pg/ml) | 799.4 (591.6, 1080.2) | 159.5 (101.9, 249.5) | 80 | <0.0001 |
vWF (ng/ml) | 12.8 (9.2, 17.9) | 8.1 (6.1, 10.8) | 37 | 0.04 |
Serum | Placebo (n = 19) | GSK1995057 (n = 18) | % reduction | P-value |
CRP (µg/ml)^{**} | 55.2 (31.0, 98.4) | 12.0 (6.6, 21.8) | 78 | 0.0007 |
OSM (pg/ml)^{***} | 20.7 (13.4, 32.0) | 7.5 (4.8, 11.7) | 64 | 0.002 |
↵* PMN data with subject classified as biological outlier (>3 x inter quartile range outside the upper quartile) removed.
↵† % Reduction and statistical significance for BALPMN data with biological outlier excluded.
↵** CRP data taken at 24h post GSK1995057 dosing. Data are adjusted means with baseline and time effects considered.
↵*** OSM data taken at 6h post LPS inhalation. Data are adjusted means with baseline and time effects considered.